Clinical Trials Sponsored by ILSI Europe

Total 2694 results

Astellas Pharma Europe B.V.

Completed

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Thromboembolism

Italy, Spain, Sweden, Austria, Denmark, Russian Federation, Poland, Bosnia and Herzegovina, Serbia, Norway, Latvia, Finland, Lithuania, Czech Republic, Germany, Slovakia, Greece
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Safety

Netherlands
Lynx Health Science GmbH
Meditrial Europe Ltd.

Recruiting

Feasibility Study for Instant Cardiac Diagnostic and Post-operative Risk Assessment With the LynxPatch Device (LP-I-CARDIAG)

Heart Diseases | Cardiovascular Diseases

Germany
ExThera Medical Europe BV
University Hospital, Essen

Not yet recruiting

Reduction of BK Viremia in Kidney Transplant Patients (CP026)

Kidney Diseases | Kidney Transplant Infection | Kidney Transplant; Complications

Germany
Radboud University Medical Center
Genzyme Europe B.V.

Recruiting

Cemiplimab for Secondary Angiosarcomas

Metastasis | Locally Advanced Sarcoma | Secondary Angiosarcoma

Netherlands
Cardiovalve Ltd.
Meditrial Europe Ltd.; Meditrial SrL

Recruiting

AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System (AHEAD)

Mitral Regurgitation | Mitral Valve Disease

Germany, Italy, Greece
Radboud University Medical Center
CytoSorbents Europe GmbH

Completed

Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis (EndoSorb)

Sepsis | Immune Deficiency | Hemoperfusion | Blood Purification

Netherlands
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register

Chronic Kidney Disease

Sweden
Cardiovascular and Interventional Radiological...

Completed

CIRSE Registry for SIR-Spheres in France (CIRT-FR) (CIRT-FR)

Liver Cancer

France
Cardiovascular and Interventional Radiological...

Completed

CIRSE Registry for LifePearl Microspheres (CIREL)

Neoplasm Metastasis | Colorectal Carcinoma

Austria
Astellas Pharma Europe B.V.

Completed

A Study of ASP8302 in Participants With Underactive Bladder

Underactive Bladder

Japan, Poland, Germany, Netherlands, Slovakia, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Czechia, France, Italy, Poland, United Kingdom
Instituto Oncológico Dr Rosell
MFAR; Bioven Europe

Completed

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C (EPICAL)

Carcinoma, Non-Small-Cell Lung

Spain
Institut de cancérologie Strasbourg Europe
LEAF4Life, Inc.

Completed

A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes

Acute Respiratory Distress Syndrome | COVID19, Sepsis or Other Causes

France
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Astellas Pharma Europe Ltd.

Terminated

A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients (PROGRESSION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Belgium, Brazil, Denmark, Hungary, Korea, Republic of, Mexico, Philippines, Poland, Turkey
Astellas Pharma Europe Ltd.

Completed

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Spain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
Astellas Pharma Europe B.V.

Completed

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) (AMARANTH)

Pain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder Disease

Belgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain
Astellas Pharma Europe Ltd.

Completed

A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant (ADDRESS)

Liver Transplant | Kidney Transplant

Italy, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (LEOPARD)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients (MITRA)

Liver Transplantation | Kidney Transplantation

France, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation (OPTION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) (PROFILE)

Inflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)

Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma Europe Ltd.

Terminated

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease (EFFECT)

Metastatic Prostate Cancer

Netherlands
PENTAX Europe GmbH
Johannes Gutenberg University Mainz

Terminated

Endomicroscopy in Ulcerative Colitis

Ulcerative Colitis

Germany, Italy
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics (VEST)

Urinary Bladder, Overactive

Czech Republic
Astellas Pharma Europe B.V.

Completed

Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia (NORMA)

Chronic Lymphocytic Leukemia

Russian Federation
Astellas Pharma Europe B.V.

Completed

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Russian Federation
Astellas Pharma Europe B.V.

Completed

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes (RUBY-1)

Acute Coronary Syndrome

Poland, Colombia, Germany, Korea, Republic of, South Africa, Czech Republic, Netherlands, Hungary, Russian Federation, Mexico, Romania, Argentina, Ukraine, Denmark, Slovakia, Belgium, India, Brazil, Australia, Canada, France
Biosensors Europe SA
Biosensors Japan Co. Ltd.

Unknown

Leaders Free Japan

Coronary Disease

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178

Healthy

France
Astellas Pharma Europe B.V.

Terminated

A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP7657 | Pharmacodynamics of ASP7657

United Kingdom
Astellas Pharma Europe B.V.

Withdrawn

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects

Healthy Volunteers | Pharmacokinetics of ASP3700
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects

Healthy Volunteers | Pharmacokinetics of ASP3700

United Kingdom
Astellas Pharma Europe Ltd.

Terminated

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

Overactive Bladder | Healthy Subjects

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652

Healthy Subjects | Pharmacokinetics of ASP3652 | Pharmacodynamics of ASP3652

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation. (SENIOR)

Kidney Transplantation

Belgium, France, Germany, Spain, Switzerland, United Kingdom, Netherlands
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Irritable Bowel Syndrome

Poland, Germany, Bulgaria, Ukraine, Estonia, Russian Federation, Czech Republic, Lithuania
Astellas Pharma Europe B.V.

Completed

Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Effect of Race

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Japanese | Caucasian

Germany
Analgesic Solutions
Pfizer; Astellas Pharma Europe B.V.

Unknown

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

Diabetes Mellitus | Painful Distal Symmetric Sensorimotor Polyneuropathy

United States
Pierrel Research Europe GmbH
Roche Pharma AG

Terminated

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation (CONVINCE)

Allogeneic Stem Cell Transplantation

Austria, Germany, Spain

Clinical Trials Sponsored by ILSI Europe

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations